Detalles de la búsqueda
1.
Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy.
J Transl Med
; 21(1): 235, 2023 03 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37004094
2.
Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study.
Front Immunol
; 14: 1061255, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36817441
3.
Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report.
J Immunother Cancer
; 8(2)2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32913031
4.
Favorable Response to Treatment with Avelumab in an HIV-Positive Patient with Advanced Merkel Cell Carcinoma Previously Refractory to Chemotherapy.
Case Rep Oncol
; 11(2): 467-475, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30140209
5.
Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
Front Immunol
; 9: 1769, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30108590
6.
Study of HER2/neu status in Qatari women with breast carcinoma.
Saudi Med J
; 24(8): 832-6, 2003 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-12939666
Resultados
1 -
6
de 6
1
Próxima >
>>